

Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients

Coding Specifications

Codes required to document patient has diabetes mellitus and a visit occurred:

A line item ICD-9-CM diagnosis code for diabetes mellitus and a CPT code are required to identify patients to be included in this measure.

All measure-specific coding should be reported ON THE SAME CLAIM.

Diabetes mellitus line item ICD-9-CM diagnosis codes

- 250.00, 250.01, 250.02, 250.03 (diabetes mellitus without mention of complication)
- 250.10, 250.11, 250.12, 250.13 (diabetes with ketoacidosis)
- 250.20, 250.21, 250.22, 250.23 (diabetes with hyperosmolarity)
- 250.30, 250.31, 250.32, 250.33 (diabetes with other coma)
- 250.40, 250.41, 250.42, 250.43 (diabetes with renal manifestations)
- 250.50, 250.51, 250.52, 250.53 (diabetes with ophthalmic manifestations)
- 250.60, 250.61, 250.62, 250.63 (diabetes with neurological manifestations)
- 250.70, 250.71, 250.72, 250.73 (diabetes with peripheral circulatory disorders)
- 250.80, 250.81, 250.82, 250.83 (diabetes with other specified manifestations)
- 250.90, 250.91, 250.92, 250.93 (diabetes with unspecified complication)
- 357.2 (polyneuropathy in diabetes)
- 362.01, 362.02, 362.03, 362.04, 362.05, 362.06, 362.07 (other retinal disorders)
- 366.41 (diabetic cataract)
- 648.00, 648.01, 648.02, 648.03, 648.04 (diabetes mellitus in pregnancy, not gestational)

AND

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a "commercial use" refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain, (even if there is no actual charge for inclusion of the measure.)

These performance measures were developed and are owned by the National Committee for Quality Assurance ("NCQA"). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2004 National Committee for Quality Assurance, all rights reserved.

Performance measures developed by NCQA for CMS may look different from the measures solely created and owned by NCQA.

PQRI 2010 Measure 119 Effective Date 01/01/2010
 © 2004 National Committee for Quality Assurance, all rights reserved.
 CPT® copyright 2009 American Medical Association

CPT codes or G-codes

- 97802, 97803, 97804
- 99201, 99202, 99203, 99204, 99205
- 99212, 99213, 99214, 99215
- 99304, 99305, 99306
- 99307, 99308, 99309, 99310
- 99324, 99325, 99326, 99327, 99328
- 99334, 99335, 99336, 99337
- 99341, 99342, 99343, 99344, 99345
- 99347, 99348, 99349, 99350
- G0270, G0271

Quality codes for this measure:

CPT II Code descriptors

(Data collection sheet should be used to determine appropriate code.)

- **CPT II 3060F:** Positive microalbuminuria test result documented and reviewed
- **CPT II 3061F:** Negative microalbuminuria test result documented and reviewed
- **CPT II 3062F:** Positive macroalbuminuria test result documented and reviewed
- **CPT II 3066F:** Documentation of treatment for nephropathy (eg, patient receiving dialysis, patient being treated for ESRD, CRF, ARF, or renal insufficiency, any visit to a nephrologist)
- **G8506:** Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy
- **CPT II 3060F OR CPT II 3061F OR CPT II 3062F with 8P:** Nephropathy screening was not performed, reason not otherwise specified